Mouse models of diffuse large B cell lymphoma
Diffuse large B cell lymphoma (DLBCL) is a genetically highly heterogeneous disease. Yet, to date, the vast majority of patients receive standardized frontline chemo-immune-therapy consisting of an anthracycline backbone. Using these regimens, approximately 65% of patients can be cured, whereas the...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1313371/full |
| _version_ | 1797403344296214528 |
|---|---|
| author | Areya Tabatabai Aastha Arora Svenja Höfmann Maximilian Jauch Bastian von Tresckow Julia Hansen Julia Hansen Julia Hansen Julia Hansen Julia Hansen Ruth Flümann Ruth Flümann Ruth Flümann Ruth Flümann Ruth Flümann Ron D. Jachimowicz Ron D. Jachimowicz Ron D. Jachimowicz Ron D. Jachimowicz Ron D. Jachimowicz Sebastian Klein Hans Christian Reinhardt Gero Knittel |
| author_facet | Areya Tabatabai Aastha Arora Svenja Höfmann Maximilian Jauch Bastian von Tresckow Julia Hansen Julia Hansen Julia Hansen Julia Hansen Julia Hansen Ruth Flümann Ruth Flümann Ruth Flümann Ruth Flümann Ruth Flümann Ron D. Jachimowicz Ron D. Jachimowicz Ron D. Jachimowicz Ron D. Jachimowicz Ron D. Jachimowicz Sebastian Klein Hans Christian Reinhardt Gero Knittel |
| author_sort | Areya Tabatabai |
| collection | DOAJ |
| description | Diffuse large B cell lymphoma (DLBCL) is a genetically highly heterogeneous disease. Yet, to date, the vast majority of patients receive standardized frontline chemo-immune-therapy consisting of an anthracycline backbone. Using these regimens, approximately 65% of patients can be cured, whereas the remaining 35% of patients will face relapsed or refractory disease, which, even in the era of CAR-T cells, is difficult to treat. To systematically tackle this high medical need, it is important to design, generate and deploy suitable in vivo model systems that capture disease biology, heterogeneity and drug response. Recently published, large comprehensive genomic characterization studies, which defined molecular sub-groups of DLBCL, provide an ideal framework for the generation of autochthonous mouse models, as well as an ideal benchmark for cell line-derived or patient-derived mouse models of DLBCL. Here we discuss the current state of the art in the field of mouse modelling of human DLBCL, with a particular focus on disease biology and genetically defined molecular vulnerabilities, as well as potential targeting strategies. |
| first_indexed | 2024-03-09T02:37:18Z |
| format | Article |
| id | doaj.art-3e77f5e60a1a436497ee58905656a659 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-09T02:37:18Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-3e77f5e60a1a436497ee58905656a6592023-12-06T08:24:48ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-12-011410.3389/fimmu.2023.13133711313371Mouse models of diffuse large B cell lymphomaAreya Tabatabai0Aastha Arora1Svenja Höfmann2Maximilian Jauch3Bastian von Tresckow4Julia Hansen5Julia Hansen6Julia Hansen7Julia Hansen8Julia Hansen9Ruth Flümann10Ruth Flümann11Ruth Flümann12Ruth Flümann13Ruth Flümann14Ron D. Jachimowicz15Ron D. Jachimowicz16Ron D. Jachimowicz17Ron D. Jachimowicz18Ron D. Jachimowicz19Sebastian Klein20Hans Christian Reinhardt21Gero Knittel22Department of Hematology and Stem Cell Transplantation, University Hospital Essen, West German Cancer Center, German Cancer Consortium Partner Site Essen, Center for Molecular Biotechnology, University of Duisburg-Essen, Essen, GermanyDepartment of Hematology and Stem Cell Transplantation, University Hospital Essen, West German Cancer Center, German Cancer Consortium Partner Site Essen, Center for Molecular Biotechnology, University of Duisburg-Essen, Essen, GermanyDepartment of Hematology and Stem Cell Transplantation, University Hospital Essen, West German Cancer Center, German Cancer Consortium Partner Site Essen, Center for Molecular Biotechnology, University of Duisburg-Essen, Essen, GermanyDepartment of Hematology and Stem Cell Transplantation, University Hospital Essen, West German Cancer Center, German Cancer Consortium Partner Site Essen, Center for Molecular Biotechnology, University of Duisburg-Essen, Essen, GermanyDepartment of Hematology and Stem Cell Transplantation, University Hospital Essen, West German Cancer Center, German Cancer Consortium Partner Site Essen, Center for Molecular Biotechnology, University of Duisburg-Essen, Essen, GermanyDepartment I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn, Cologne, GermanyCenter for Molecular Medicine, University of Cologne, Cologne, GermanyCologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, GermanyMildred Scheel School of Oncology Aachen Bonn Cologne Düsseldorf (MSSO ABCD), Faculty of Medicine and University Hospital of Cologne, Cologne, GermanyMax Planck Institute for Biology of Ageing, Cologne, GermanyDepartment I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn, Cologne, GermanyCenter for Molecular Medicine, University of Cologne, Cologne, GermanyCologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, GermanyMildred Scheel School of Oncology Aachen Bonn Cologne Düsseldorf (MSSO ABCD), Faculty of Medicine and University Hospital of Cologne, Cologne, GermanyMax Planck Institute for Biology of Ageing, Cologne, GermanyDepartment I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn, Cologne, GermanyCenter for Molecular Medicine, University of Cologne, Cologne, GermanyCologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, GermanyMildred Scheel School of Oncology Aachen Bonn Cologne Düsseldorf (MSSO ABCD), Faculty of Medicine and University Hospital of Cologne, Cologne, GermanyMax Planck Institute for Biology of Ageing, Cologne, GermanyDepartment of Hematology and Stem Cell Transplantation, University Hospital Essen, West German Cancer Center, German Cancer Consortium Partner Site Essen, Center for Molecular Biotechnology, University of Duisburg-Essen, Essen, GermanyDepartment of Hematology and Stem Cell Transplantation, University Hospital Essen, West German Cancer Center, German Cancer Consortium Partner Site Essen, Center for Molecular Biotechnology, University of Duisburg-Essen, Essen, GermanyDepartment of Hematology and Stem Cell Transplantation, University Hospital Essen, West German Cancer Center, German Cancer Consortium Partner Site Essen, Center for Molecular Biotechnology, University of Duisburg-Essen, Essen, GermanyDiffuse large B cell lymphoma (DLBCL) is a genetically highly heterogeneous disease. Yet, to date, the vast majority of patients receive standardized frontline chemo-immune-therapy consisting of an anthracycline backbone. Using these regimens, approximately 65% of patients can be cured, whereas the remaining 35% of patients will face relapsed or refractory disease, which, even in the era of CAR-T cells, is difficult to treat. To systematically tackle this high medical need, it is important to design, generate and deploy suitable in vivo model systems that capture disease biology, heterogeneity and drug response. Recently published, large comprehensive genomic characterization studies, which defined molecular sub-groups of DLBCL, provide an ideal framework for the generation of autochthonous mouse models, as well as an ideal benchmark for cell line-derived or patient-derived mouse models of DLBCL. Here we discuss the current state of the art in the field of mouse modelling of human DLBCL, with a particular focus on disease biology and genetically defined molecular vulnerabilities, as well as potential targeting strategies.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1313371/fulldiffuse large B cell lymphoma (DLBCL)genetically engineered (GE) animalslymphomaanimal modelsmouse models |
| spellingShingle | Areya Tabatabai Aastha Arora Svenja Höfmann Maximilian Jauch Bastian von Tresckow Julia Hansen Julia Hansen Julia Hansen Julia Hansen Julia Hansen Ruth Flümann Ruth Flümann Ruth Flümann Ruth Flümann Ruth Flümann Ron D. Jachimowicz Ron D. Jachimowicz Ron D. Jachimowicz Ron D. Jachimowicz Ron D. Jachimowicz Sebastian Klein Hans Christian Reinhardt Gero Knittel Mouse models of diffuse large B cell lymphoma Frontiers in Immunology diffuse large B cell lymphoma (DLBCL) genetically engineered (GE) animals lymphoma animal models mouse models |
| title | Mouse models of diffuse large B cell lymphoma |
| title_full | Mouse models of diffuse large B cell lymphoma |
| title_fullStr | Mouse models of diffuse large B cell lymphoma |
| title_full_unstemmed | Mouse models of diffuse large B cell lymphoma |
| title_short | Mouse models of diffuse large B cell lymphoma |
| title_sort | mouse models of diffuse large b cell lymphoma |
| topic | diffuse large B cell lymphoma (DLBCL) genetically engineered (GE) animals lymphoma animal models mouse models |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1313371/full |
| work_keys_str_mv | AT areyatabatabai mousemodelsofdiffuselargebcelllymphoma AT aasthaarora mousemodelsofdiffuselargebcelllymphoma AT svenjahofmann mousemodelsofdiffuselargebcelllymphoma AT maximilianjauch mousemodelsofdiffuselargebcelllymphoma AT bastianvontresckow mousemodelsofdiffuselargebcelllymphoma AT juliahansen mousemodelsofdiffuselargebcelllymphoma AT juliahansen mousemodelsofdiffuselargebcelllymphoma AT juliahansen mousemodelsofdiffuselargebcelllymphoma AT juliahansen mousemodelsofdiffuselargebcelllymphoma AT juliahansen mousemodelsofdiffuselargebcelllymphoma AT ruthflumann mousemodelsofdiffuselargebcelllymphoma AT ruthflumann mousemodelsofdiffuselargebcelllymphoma AT ruthflumann mousemodelsofdiffuselargebcelllymphoma AT ruthflumann mousemodelsofdiffuselargebcelllymphoma AT ruthflumann mousemodelsofdiffuselargebcelllymphoma AT rondjachimowicz mousemodelsofdiffuselargebcelllymphoma AT rondjachimowicz mousemodelsofdiffuselargebcelllymphoma AT rondjachimowicz mousemodelsofdiffuselargebcelllymphoma AT rondjachimowicz mousemodelsofdiffuselargebcelllymphoma AT rondjachimowicz mousemodelsofdiffuselargebcelllymphoma AT sebastianklein mousemodelsofdiffuselargebcelllymphoma AT hanschristianreinhardt mousemodelsofdiffuselargebcelllymphoma AT geroknittel mousemodelsofdiffuselargebcelllymphoma |